Semaglutides ability to produce insulin and reduce blood sugar made the compound a desirable Type 2 diabetic treatment option
Furthermore, a prespecified subgroup analysis of HF individuals from the SELECT trial evaluating the effects of semaglutide on cardiovascular outcomes in people with overweight or obesity, which included 2,273 HFpEF and 1,347 HFrEF patients, showed that the therapy was associated with a reduction in the HF composite outcome (cardiovascular death or HF hospitalisation/emergency visit) across LVEF, suggesting that GLP-1 RAs may improve outcomes at least in obese HF patients regardless of diabetes status
Some patients report skin irritation at injection sites, in particular
Mean values were compared using an unpaired 2-tailed Students t test
Research shows that individuals with obesity often have lower baseline GLP-1 secretion compared to those with healthy weight ranges
Melanie Avalon I got really good at it and I did it like every day for a couple months and then it was pretty easy to do, but it does require, I don't even remember how long it took